Major U.S. Pfizer Brands
U.S. Sales Driven by Massive Price Increases as Rxs Eroded
Other Major U.S. Brands
Pfizer’s Lyrica (seizures/nerve pain, on U.S. market since 2004)
- 2005 Reported U.S. Sales: $717 million
- 2017 Reported U.S. Sales: $3.5 billion
- 2017 U.S. Sales WITHOUT Price Increases: $1.16 billion
- Cumulative harm since start of Part D: $10.0+ billion
Other major U.S. Pfizer brands:
- Strong U.S. sales growth driven by severe prices increases
- As clinical use sharply declined
- Premarin (hormone replacement)
- Viagra: (impotence)
- Celebrex (arthritis, pain)
- Chantix (smoking cessation)
- Link to U.S. Pfizer severe price increase and declining prescription trends
- Link to the summary of U.S. sales and "pharma fee" abuse from the Southern District of New York (SDNY) whistleblower case, including key Pfizer U.S. brands